Biomedical Innovation and Equitable Access

To the Editor In their Viewpoint,1 Dr Dzau and colleagues paint an intriguing metaphorical picture of 2 successive “valleys of death” that prevent biomedical innovation from advancing health care for the general public.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2025-04-16
DOI
https://doi.org/10.1001/jama.2025.0983
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomedical Innovation and Equitable Access

Klaus Lindpaintner
JAMA
Pharmaceutical Economics and Policy
article

Biomedical Innovation and Equitable Access

Klaus Lindpaintner
article en

Abstract

To the Editor In their Viewpoint,1 Dr Dzau and colleagues paint an intriguing metaphorical picture of 2 successive “valleys of death” that prevent biomedical innovation from advancing health care for the general public.

JAMAVol. 333(19)
Bruker (United States) (US), Scientific Solutions (United States) (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 89%
Pharmaceutical Economics and Policy
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Biomedical Innovation and Equitable Access — Klaus Lindpaintner · JAMA (2025) | TGRS Research Map | TGRS